Although these markers need to be validated in larger and different ethnic cohorts and prospective studies are warranted before using them in the clinic, the simplicity of immunostaining and assessment by IRS makes these proteins interesting candidates for personalizing CRC treatment. Here, IARS1 is linked to colorectal carcinoma.